Angion
- Business Wire
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Topline data expected in the second half of 2021 ST. GALLEN, Switzerland & UNIONDALE, NY–(BUSINESS WIRE)–Regulatory News: Vifor Pharma and…
Read More » - Business
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
St. Gallen, Switzerland & Uniondale, N.Y., United States: Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is…
Read More »